Do you want to read an article? Please log in or register.
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
Lung Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lung Cancer
Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JC, Bajars M, Ruisi M, Manitz J, Barlesi F
doi: 10.1016/j.lungcan.2021.01.026
RECOMMENDED
Lung Cancer
Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Andreano A, Bergamaschi W, Russo AG
doi: 10.1016/j.lungcan.2021.06.019
RECOMMENDED
Lung Cancer
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Passiglia F, Leone G, Olmetto E, Delcuratolo MD, Tabbò F, Reale ML, Bertaglia V, Consito L, Bironzo P, Capelletto E, Novello S
doi: 10.1016/j.lungcan.2021.05.009
RECOMMENDED
Lung Cancer
Management of pulmonary toxicity associated with immune checkpoint inhibitors
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir Rev.
Delaunay M, Prévot G, Collot S, Guilleminault L, Didier A, Mazières J
doi: 10.1183/16000617.0012-2019.
RECOMMENDED
Lung CancerPleural DiseasesFurther Publications
Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities
Chest.
Suresh K, Naidoo J, Lin CT, Danoff S
doi: 10.1016/
RECOMMENDED
Further Publications
Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP, Rivera MP
doi: 10.1016/j.chest.2021.02.032
RECOMMENDED
Lung Cancer
Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer.
Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboynik M, Moore M, Shackleton M, Haydon A, John T, Mitchell PLR, Markman B, Briggs P, Parakh S
doi: 10.1016/j.cllc.2020.06.001.
RECOMMENDED
Lung Cancer
The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer.
Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, Villaflor VM
doi: 10.1016/j.cllc.2020.07.016.
RECOMMENDED
Lung Cancer
Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, Khosravi-Shahi P
doi: 10.1016/j.cllc.2021.03.006